-Q2, 2024 total revenues of $15.8 million grew +14% Y/Y and +7.7% Q/Q based on strong demand and output in the TrinScreen HIV business- -Point-of-Care product revenue of $4.6 million grew 119% Y/Y and +53% Q/Q- -Reiterating guidance to achieve approximately $20 million of annualized run-rate EBITDASO1 on annualized runrate revenues of approximately $75 million by Q2, 2025- DUBLIN, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human ...

DUBLIN, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the "Company"), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, will report financial results for the second quarter 2024 on Wednesday, August 14, 2024 at 8:30 AM ET. | --- | --- | |----------------|----------------------------------------------------------------------------| | Date: | Conference Call Dial-In & Webcast Information \nWednesday, ...

DUBLIN, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, obtained an extension to demonstrate compliance with a continued listing requirement of The Nasdaq Global Select Market. As previously reported in a Current Report on Form 6-K filed November 29, 2023, the Company received a deficiency letter from the Listing Qualifications Department of The Nasdaq ...

-Second Quarter 2024 revenues are expected to fall between $15.5-$16.0 million, reflecting double digit percentage year over year growth- -Reiterating financial guidance of approximately $20 million of annualized run-rate EBITDASO1 on annualized run-rate revenues of approximately $75 million by Q2 2025- -Entered into MedScience distribution agreement in UK effective as of August 1, 2024 which encompasses clinical chemistry, infectious disease, and autoimmune products- DUBLIN, Aug. 02, 2024 (GLOBE NEWSWIRE) ...

文章核心观点 - 公司第二季度2024年收入预计在1550万美元至1600万美元之间,同比增长双位数百分比 [1] - 公司重申到2025年第二季度实现年化运营收入约7500万美元,年化运营EBITDASO1约2000万美元的财务指引 [2][7] - 公司与英国医疗科学公司MedScience签署分销协议,涵盖临床化学、传染病和自身免疫产品 [3][4][6] 公司概况 - 公司是一家专注于人体诊断和糖尿病管理解决方案的商业阶段生物技术公司,包括可穿戴生物传感器 [10] - 公司开发、收购、制造和销售诊断系统,包括试剂和仪器,用于临床实验室和现场诊断市场,最近还进入了可穿戴生物传感器行业 [10] - 公司产品用于检测传染病,并量化血红蛋白A1c和其他化学参数的水平 [10] - 公司在美国直接销售,并通过遍布全球75个国家的国际分销商和战略合作伙伴网络进行销售 [10] MedScience公司概况 - MedScience是Pharmed集团的一家子公司,是英国领先的医疗和科学设备、耗材和服务提供商 [11] - 公司与全球领先制造商签有独家分销协议,为实验室、医疗和科学服务提供商提供最先进的产品 [11] - 公司在英国拥有现代化的总部办公室、仓储和内部维修团队,为客户提供全面的支持 [11]

Louise Tallon responded, "I'm excited to join the Trinity Biotech team and look forward to contributing to its exciting vision to become a highly profitable organisation, intent on executing its development and launch of a next generation CGM device." This release includes statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"), including but not limited to statements related to Trinity Biotech's cash position, fin ...

Commenting on the appointment, John Gillard, CEO of Trinity Biotech plc, said "We are delighted to welcome Louise, who brings extensive experience in transformation and growth within a dynamic environment. This skill set, combined with her extensive experience in the life sciences product commercialisation industry, will elevate the continued development of the organisation as we continue to deliver on our corporate strategy of delivering our comprehensive transformation plan and introducing our next genera ...

This pre-pivotal trial will begin imminently and is expected to be completed by the end of July. The study will assess the analytical performance of CGM technology enhancements implemented by Trinity Biotech. The data from this analytical performance assessment will be utilised to advance the technical optimization of the next generation CGM device ahead of the pivotal trial that is planned in 2025. Forward-Looking Statements Gary Keating, Ph.D. Eric Ribner (353)-1-2769800 (1)-646-751-4363 E-mail: investorr ...

This pre-pivotal trial will begin imminently and is expected to be completed by the end of July. The study will assess the analytical performance of CGM technology enhancements implemented by Trinity Biotech. The data from this analytical performance assessment will be utilised to advance the technical optimization of the next generation CGM device ahead of the pivotal trial that is planned in 2025. Trinity Biotech President and Chief Executive Officer, Mr John Gillard stated "We believe our CGM solution an ...

About Trinity Biotech Management plans to host meetings with key stakeholders and potential partners as it works to advance the next generation of its recently acquired continuous glucose monitoring (CGM) biosensor technology. Interested parties are invited to reach out for more information by emailing Biosensors@trinitybiotech.com. To learn more about Trinity's CGM, please visit https://cgm.trinitybiotech.com LifeSci Partners, LLC Eric Ribner (1)-646-751-4363 E-mail: investorrelations@trinitybiotech.com Co ...